185225-06-3

Basic information

• Product Name: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one
• Synonyms: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one
• CAS NO: 185225-06-3
• Molecular Formula: C22H26O5
• Molecular Weight: 370.44
• Mol File: 185225-06-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 546.8°C at 760 mmHg
• Flash Point: 238.3°C
• Appearance: /
• Density: 1.18
• Vapor Pressure: 5.2E-12mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(185225-06-3)
• EPA Substance Registry System: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(185225-06-3)

Safety Data

• Hazardous Substances Data: 185225-06-3(Hazardous Substances Data)

Usage

General Description

(3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one is a chemical compound with a complex structure featuring several functional groups. It consists of a hexahydro-2H-cyclopenta[b]furan-2-one core, featuring a five-membered lactone ring with a saturated furan ring fused onto it. The compound also possesses a benzoyloxy group, which is essentially an ester formed between benzoyl chloride and an alcohol. Additionally, it contains a 3-oxo-1-octen-1-yl side chain, indicating a presence of an octene with a ketone functional group at the 3rd carbon. The naming of this molecule follows the standard IUPAC rules, and the letters (3aR,4R,5R,6aS) before the name describe the absolute configuration of its chiral centers. Therefore, this chemical is likely to be of interest in fields such as medicinal or organic chemistry due to its intricate structure.

InChI:InChI=1/C22H26O5/c1-2-3-5-10-16(23)11-12-17-18-13-21(24)26-20(18)14-19(17)27-22(25)15-8-6-4-7-9-15/h4,6-9,11-12,17-20H,2-3,5,10,13-14H2,1H3/b12-11+/t17-,18-,19-,20+/m1/s1

Upstream product

• 36969-89-8 dimethyl 2-oxoheptylphosphonate 
• 39746-01-5 Benzoic acid (3aR,4R,5R,6aS)-4-formyl-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 172821-93-1 C₁₅H₁₆O₅ 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 33803-58-6 1-(triphenylphosphoranylidene)-2-heptanone 
• 61728-15-2 2-oxohexylphosphonic acid dimethyl ester 
• 110-43-0 n-pentyl methyl ketone 

Downstream Products

• 60203-57-8 prostaglandin J₂ 
• 38873-82-4 (15R)-PGE2 

Relevant articles and documents

Preparation method of carboprost tromethamine intermediate

The invention provides a preparation method of a carboprost tromethamine intermediate. The method comprises the following steps: A) carrying out an oxidation reaction on benzoyl corey lactone alcohol shown in a formula I under the action of a catalyst and an oxidizing agent to obtain benzoyl corey lactone aldehyde shown in a formula II; B) reacting the benzoyl corey lactone aldehyde as shown in the formula II with dimethyl (2-oxoheptyl) phosphonate under the action of alkali to obtain a 15-ketone crude product as shown in a formula III, and recrystallizing the 15-ketone crude product to obtain a 15-ketone pure product; and C) carrying out methylation reaction on the 15-ketone pure product to obtain the carboprost tromethamine intermediate as shown in a formula IV. According to the invention, the use of reagents with high toxicity and serious environmental pollution is avoided; when the carboprost intermediate 15-ketone is prepared, a mixed solvent is adopted for recrystallization, so that column chromatography is omitted, operation is easy and convenient, reagents are saved, and cost is reduced; and in the methylate preparation process, ultralow temperature is avoided, and the reaction time is shortened, so that the energy consumption is reduced, and the purity and the yield are relatively high.

PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS

A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysm

Method for preparing prostaglandin derivative

Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as sole base. By carrying out the reaction using an alkali hydroxide as sole base in the reaction system, the desired prostaglandin derivative can be obtained by simple procedures and with high yield.